Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04689828
Title 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

prostate adenocarcinoma

Therapies

lutetium Lu 177 vipivotide tetraxetan

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.